Today’s Short Interest Alert: Therapeuticsmd (NYSEMKT:TXMD) Reports Increase in Sellers; Strong Momentum for Short Players

November 18, 2016 - By Darrin Black   ·   0 Comments

Today's Short Interest Alert: Therapeuticsmd (NYSEMKT:TXMD) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of Therapeuticsmd (NYSEMKT:TXMD) registered an increase of 2.19% in short interest. TXMD’s total short interest was 38.97 million shares in November as published by FINRA. Its up 2.19% from 38.14 million shares, reported previously. With 1.07 million shares average volume, it will take short sellers 36 days to cover their TXMD’s short positions. The short interest to Therapeuticsmd’s float is 30.14%. About 185,020 shares traded hands. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 13.41% since April 18, 2016 and is downtrending. It has underperformed by 17.84% the S&P500.

TherapeuticsMD, Inc. is a women’s healthcare product company. The company has a market cap of $1.41 billion. The Company’s segment is creating and commercializing products for women. It currently has negative earnings. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products.

Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.07, from 1.25 in 2016Q1. The ratio is positive, as 19 funds sold all TherapeuticsMD Inc shares owned while 29 reduced positions. 13 funds bought stakes while 47 increased positions. They now own 158.58 million shares or 4.25% more from 152.12 million shares in 2016Q1.
Wells Fargo Mn reported 260,355 shares or 0% of all its holdings. Teachers last reported 237,923 shares in the company. Retail Bank Of America Corp De last reported 0% of its portfolio in the stock. Stifel has 261,674 shares for 0.01% of their US portfolio. Burns J W And New York accumulated 25,275 shares or 0.07% of the stock. Morgens Waterfall Vintiadis has 1.41% invested in the company for 180,000 shares. Barometer Cap Management holds 0.05% or 53,800 shares in its portfolio. Great West Life Assurance Can holds 15,700 shares or 0% of its portfolio. Moreover, Guggenheim Capital Ltd Liability Co has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 11,513 shares. Paradigm Asset Mngmt Com Limited Liability Com has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Weiss Multi holds 0.02% or 31,347 shares in its portfolio. The New Jersey-based Blackrock Inv Management Ltd Liability Corporation has invested 0.01% in TherapeuticsMD Inc (NYSEMKT:TXMD). The Massachusetts-based Massachusetts Financial Serv Ma has invested 0.01% in TherapeuticsMD Inc (NYSEMKT:TXMD). Blackrock Advisors Llc has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Goldman Sachs Group Inc Inc holds 0% or 87,471 shares in its portfolio.

TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage

Out of 3 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TherapeuticsMD has been the topic of 4 analyst reports since September 21, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock with “Buy” rating in Tuesday, December 8 report. Stifel Nicolaus maintained it with “Buy” rating and $14.0 target price in Tuesday, December 8 report. The rating was maintained by Jefferies with “Buy” on Monday, September 21.

TXMD Company Profile

TherapeuticsMD, Inc., incorporated on July 20, 2010, is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company’s drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. The Company’s drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Firm makes and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins.

Another recent and important TherapeuticsMD Inc (NYSEMKT:TXMD) news was published by Fool.com which published an article titled: “Is This Why Shares of TherapeuticsMD Inc. Rose Today?” on November 04, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>